A synthetic peptide from internal region of human CTRP5 conjugated to an immunogenic carrier protein was used as the antigen. The antigen is homologous in rat and mouse.
IHC, WB. A concentration of 10-50 μg,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Reconstitute in 500 μL of sterile water. Centrifuge to remove any insoluble material.
Conseil sur la manipulation
Avoid freeze and thaw cycles.
Stock
4 °C/-20 °C
Stockage commentaire
Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
Date de péremption
12 months
Antigène
CTRP5 (C1QTNF5)
(C1q and Tumor Necrosis Factor Related Protein 5 (C1QTNF5))
anticorps C1QTNF5, anticorps wu:fb02c10, anticorps wu:fb02f05, anticorps zgc:112378, anticorps CTRP5, anticorps Ctrp5, anticorps C1q and tumor necrosis factor related protein 5, anticorps C1q and TNF related 5, anticorps C1QTNF5, anticorps c1qtnf5, anticorps C1qtnf5
Sujet
Defects in C1QTNF5 are a cause of late-onset retinal degeneration (LORD). LORD is an autosomal dominant disorder characterized by onset in the fifth to sixth decade with night blindness and punctate yellow-white deposits in the retinal fundus, progressing to severe central and peripheral degeneration, with choroidal neovascularization and chorioretinal atrophy. Subcellular location: Secreted,Vision,Complement C1q tumor necrosis factor-related protein 5, C1QTNF5